12/29/2014 - 12:26pm

Genentech last week announced that the Food and Drug Administration approved a supplemental biologics license application for Gazyva to be used in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia.

12/29/2014 - 11:29am

Novo Nordisk last week announced that the Food and Drug Administration approved the company's new drug application for Saxenda, a once-daily glucagon-like peptide-1 receptor agonist used as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults.

12/29/2014 - 11:07am

Actavis and Adamas Pharmaceuticals last week announced that the Food and Drug Administration approved Namzaric. According to the companies, the drug is used to treat moderate to severe dementia of the Alzheimer's type in patients stablized on memantine hydrochloride and donepezil hydrochloride.

 

12/17/2014 - 4:49pm

The Food and Drug Administration on Wednesday approved Xtoro (finafloxacin otic suspension), a new drug that's used to treat acute otitis externa, commonly known as swimmer's ear. 

12/16/2014 - 12:26pm

 Greenstone announced the launch of celecoxib — the authorized generic version of Pfizer's Celebrex — to its line of generic pharmaceuticals. 

12/16/2014 - 11:27am

Novartis on Tuesday received approval from the Food and Drug Administration for Signifor long-acting release (pasireotide) for injectable suspension, for intramuscular use. 

 

12/16/2014 - 11:14am

Dr. Reddy's Labs announced the launch of valganciclovir tablets USP in 450-mg strength. 

 

12/11/2014 - 3:24pm

Teva Pharmaceuticals on Thursday announced the availability of levalbuterol inhalation solution, USP (concentrate), a generic equivalent to Xopenex inhalation solution concentrate. 

12/11/2014 - 3:15pm

Lupin Pharmaceuticals launched the authorized generic version of Celebrex capsules in 50-, 100-, 200- and 400-mg dosage strengths.